Exelixis’ and Sankyo’s Cardiovascular Collaboration
By Business Review Editor
Pharma Deals Review: Vol 2006 Issue 70 (Table of Contents)
Published: 6 Apr-2006
DOI: 10.3833/pdr.v2006.i70.529 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Exelixis entered into an agreement with Sankyo to develop and commercialize novel therapies targeted against mineralocorticoid receptor which is implicated in a variety of cardiovascular and metabolic disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018